Recurrence of focal segmental glomerulosclerosis in renal allograft: An in-depth review

Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: An in‐depth review.
Pediatr Transplantation 2010: 14: 314–325. © 2010 John Wiley & Sons A/S. :  Focal segmental glomerulosclerosis is a major cause of chronic kidney disease requiring transplantati...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric transplantation 2010-05, Vol.14 (3), p.314-325
Main Authors: Vinai, Modini, Waber, Pamela, Seikaly, Mouin G.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Biological and medical sciences
Calcineurin Inhibitors
Child
children
FSGS
General aspects
Glomerulonephritis
Glomerulosclerosis, Focal Segmental - diagnosis
Glomerulosclerosis, Focal Segmental - surgery
Glomerulosclerosis, Focal Segmental - therapy
Graft Rejection
Humans
Immunologic Factors - therapeutic use
Immunosuppressive Agents - therapeutic use
kidney
Kidney Transplantation
Medical sciences
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Recurrence
Risk Factors
Rituximab
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
transplant
Transplantation, Homologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: An in‐depth review.
Pediatr Transplantation 2010: 14: 314–325. © 2010 John Wiley & Sons A/S. :  Focal segmental glomerulosclerosis is a major cause of chronic kidney disease requiring transplantation in children. Recurrence rate in the renal allograft transplantation is as high as 50%. Recurrence of FSGS is associated with renal dysfunction and early graft loss. To date, there is no established therapy for recurrent FSGS after renal transplant. We have reviewed the current English literature in order to summarize current practices with emphasis on graft outcome. We conclude that despite multiple approaches to the post transplant management of recurrent FSGS, none have been shown to be consistently beneficial. Currently, pheresis combined with high dose anti‐calcineurin with or without rituximab seems to be the most promising. Further controlled studies are needed to define the optimal therapeutic regimens to treat recurrent of FSGS.
ISSN:1397-3142
1399-3046
DOI:10.1111/j.1399-3046.2009.01261.x